Browse the evidence

Human hypothalamic melanocortin neurons (POMC and AgRP) exhibit significant transcriptomic and receptor-expression differences compared to mice, including species-specific GPCR profiles that directly impact the mechanism and efficacy of current obesity therapies.

Current obesity treatments like semaglutide and tirzepatide target the hypothalamus, but their exact molecular mechanisms in humans may differ from what we learned from mouse studies. This map reveals that human POMC neurons express different receptors (like CALCR) than mouse POMC neurons. This means drug developers must account for these human-specific differences to improve efficacy and reduce side effects, rather than relying solely on rodent data.

SGLT-2 inhibitors provide cardiovascular and renal protective benefits independent of their glucose-lowering effects, including reduced risk of heart failure hospitalization and worsening renal function.

SGLT-2 inhibitors (like Jardiance or Farxiga) are not just for blood sugar. They are now a standard treatment for heart failure and kidney disease, even in people without diabetes. They significantly reduce the risk of being hospitalized for heart failure and slow down kidney damage. If you have heart or kidney issues, ask your doctor if this class of medication is appropriate for you.

Estrogen therapy does not reduce cardiovascular disease events and may increase stroke risk in postmenopausal women, particularly those with diabetes, and is not recommended for chronic disease prevention.

Do not use estrogen to prevent heart disease. It does not work for this purpose and may increase stroke risk. If you have severe menopausal symptoms and are at low risk for other issues, it may be used for symptom relief, but risk calculators should guide this decision.

SGLT-2 inhibitors slow the progression of chronic kidney disease (CKD) and reduce the risk of end-stage kidney disease (ESKD) in patients with type 2 diabetes and albuminuria.

If you have diabetes and early kidney disease (albuminuria), SGLT-2 inhibitors (like Jardiance or Invokana) are recommended to protect your kidneys. They slow down the decline of kidney function and reduce the risk of needing dialysis, even if your blood sugar is already controlled.

SGLT-2 inhibitors reduce the risk of worsening heart failure and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status.

If you have heart failure with a weak pumping heart (HFrEF), SGLT-2 inhibitors (like Jardiance or Farxiga) are now a standard part of treatment. They reduce hospitalizations and death, even if you don't have diabetes. They help your heart pump more efficiently.

SGLT2 inhibitors significantly reduce heart failure hospitalizations and cardiovascular death in patients with Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF), regardless of diabetes status.

If you have Heart Failure (whether your heart pumps strongly or weakly), SGLT2 inhibitors (Dapagliflozin or Empagliflozin) are a cornerstone treatment that reduces hospitalizations and death, even if you do not have Diabetes. Ask your cardiologist about these medications.

GIP is the major physiological mediator of the incretin effect in healthy humans, contributing more to insulin secretion than GLP-1.

In healthy individuals, GIP is the primary driver of the 'incretin effect' (the boost in insulin after eating). This physiological fact underpins the rationale for using dual GIP/GLP-1 drugs in diabetes.

SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) reduce cardiovascular mortality and heart failure hospitalization in type 2 diabetes patients, primarily through hemodynamic effects (osmotic diuresis and natriuresis) rather than glucose-lowering.

If you have Type 2 Diabetes and heart or kidney issues, SGLT2 inhibitors (like empagliflozin or dapagliflozin) are now considered a primary treatment option. They protect your heart and kidneys through fluid balance mechanisms, not just by lowering sugar. Discuss with your doctor if you are a candidate, especially if you have existing heart disease or kidney impairment.

Adipocyte ACLY facilitates the activation of the transcription factor ChREBP, which is necessary for glucose uptake and de novo lipogenesis in adipose tissue.

This mechanism highlights why healthy fat storage is important for metabolic health. If the enzymes that help fat cells store energy properly are disrupted, sugar may end up in the liver instead, causing harm.

The PI3K-Akt-mTOR signaling pathway is a key mechanism linking obesity and diabetes to cancer, as it is sensitive to nutrient status and cell energy states.

Understanding that high insulin and nutrient levels activate cancer-promoting pathways highlights why maintaining healthy weight and blood sugar is crucial for cancer prevention.

Tanycytic release of VEGF-A is the mechanistic mediator that allows hypoglycemia to increase GLP-1 receptor agonist entry into the brain.

This is a basic science finding. It suggests that the health of specialized brain cells (tanycytes) and their production of VEGF are critical for GLP-1 drugs to work centrally.

SGLT2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status.

If you have heart failure, especially with reduced ejection fraction, ask your doctor about SGLT2 inhibitors like empagliflozin or dapagliflozin. These drugs help your heart pump better and reduce hospitalizations, even if you don't have diabetes.

Interventions that delay or prevent the onset of type 2 diabetes in overweight/obese subjects with dysglycemia do not reduce the subsequent development or prevalence of diabetic retinopathy for up to 20 years.

If you have prediabetes or are at risk for type 2 diabetes, preventing or delaying the onset of diabetes through lifestyle changes or medication (like metformin) does not guarantee that you will avoid eye damage (retinopathy). Retinopathy can start during the prediabetic stage. Therefore, regular eye exams are crucial for people with prediabetes, regardless of whether they successfully prevent diabetes.

Insulin-lowering diets have not yet been conclusively demonstrated to improve cancer-specific endpoints such as tumor response, disease-specific survival, or overall survival in clinical settings.

Do not rely on insulin-lowering diets as a cure or primary treatment for metastatic cancer. While they improve metabolic health and are safe, they have not been proven to extend life or shrink tumors in humans. Use them only as an adjunct to standard care under medical supervision.

Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, significantly reduces cardiovascular death, all-cause mortality, and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk.

If you have type 2 diabetes and are at high risk for heart problems, empagliflozin is a medication that can significantly lower your risk of dying from heart issues, dying from any cause, and being hospitalized for heart failure. It works by helping your kidneys remove sugar and water, which also helps lower blood pressure and weight. While it does increase the risk of genital infections, the cardiovascular benefits are substantial for high-risk individuals.

Endogenous GLP-1 is primarily secreted by intestinal L-cells in response to nutrient contact, not by pancreatic alpha-cells.

Your body naturally produces GLP-1 from your intestines when you eat. This hormone helps regulate blood sugar and appetite. Dietary fiber and nutrients stimulate this natural release.

Native GLP-1 has a very short half-life (1-2 minutes) due to rapid degradation by the enzyme DPP-4, necessitating biochemically modified agonists for clinical use.

Your body breaks down natural GLP-1 very quickly. Medications like Ozempic or Wegovy are chemically modified to resist this breakdown, allowing them to work for days instead of minutes.

Activation of the NLRP3 inflammasome in macrophages leads to the secretion of IL-1β and IL-18, which impair insulin signaling and contribute to beta-cell apoptosis in Type 2 Diabetes.

Chronic inflammation in fat tissue activates specific immune pathways (NLRP3 inflammasome) that release harmful cytokines (IL-1β). These cytokines damage insulin signaling and beta-cells. Addressing inflammation may help protect these cells.

Albumin binding via fatty acid derivatization extends the half-life of GLP-1 analogs, enabling once-daily (liraglutide) or once-weekly (semaglutide) dosing.

The drugs are designed to bind to albumin in the blood, which keeps them in the body longer. This allows for less frequent dosing (daily or weekly) compared to the natural hormone, which breaks down quickly.

Type 2 diabetes risk in Europeans is predominantly driven by common genetic variants of modest effect size, with no novel low-frequency variants of moderate-to-strong effect detected despite extensive sample sizes.

This research indicates that for most people of European ancestry, Type 2 Diabetes risk is largely determined by common genetic factors with small individual effects, rather than rare, high-impact mutations. This means lifestyle interventions remain critical because they address the environmental and physiological pathways (insulin secretion, action) that these genes influence, even if the genetic risk itself cannot be changed.

Autoimmune thyroid disease (AITD) is significantly more prevalent in patients with Type 1 Diabetes (T1D) than in the general population, sharing common genetic susceptibility factors.

If you have Type 1 Diabetes, you are at a much higher risk for autoimmune thyroid disease (17-30% prevalence). Regular screening for thyroid function (TSH) and antibodies (TPO) is recommended, even if you feel healthy, to prevent complications and ensure optimal diabetes management.

Hepatic insulin resistance, characterized by failure to suppress hepatic glucose production (gluconeogenesis and glycogenolysis), is a major feature of type 2 diabetes pathophysiology.

Managing fasting blood glucose often requires addressing hepatic glucose output, which can be influenced by weight loss and specific medications that target liver insulin sensitivity.

Levothyroxine therapy does not improve thyroid-related symptoms or quality of life in older adults (≥65 years) with subclinical hypothyroidism.

If you are over 65 and have subclinical hypothyroidism (high TSH but normal T4), taking levothyroxine is unlikely to make you feel less tired or improve your quality of life. While the medication will lower your TSH levels, it does not appear to provide clinical benefits for symptoms in this age group.

PPARgamma mutations (loss-of-function) cause familial partial lipodystrophy type 3 (FPLD3), characterized by lack of subcutaneous fat in extremities and metabolic complications like type 2 diabetes.

Fat distribution is partly genetic. If you have a rare condition like FPLD3, your fat distribution and metabolic risks are driven by specific genetic mutations.